HomeProductsBioactive CompoundsCell CycleCasein KinaseUmbralisib
Chemical structure of CAS 1532533-67-7

Umbralisib

CAS No.1532533-67-7
MDL No.MFCD28386165
MFC31H24F3N5O3
MW571.50
InChI KeyIUVCFHHAEHNCFT-INIZCTEOSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1532533-67-7
Product NameUmbralisib

Biological Targets

CSNK1E·PIK3CD·ABL1

Associated Conditions

lymphoma·neoplasm of mature B-cells·chronic lymphocytic leukemia·Hodgkins lymphoma·myelofibrosis·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.

The Lancet. Oncology • Vol. 19, Issue 4 • 2018
PMID: 29475723DOI: 10.1016/S1470-2045(18)30082-2

Can umbralisib bring PI3Kδ out of the shadows?

The Lancet. Oncology • Vol. 19, Issue 4 • 2018
PMID: 29475725DOI: 10.1016/S1470-2045(18)30154-2

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies.

Blood • Vol. 129, Issue 1 • 2017
PMID: 27784673PMC: PMC5216267DOI: 10.1182/blood-2016-08-731240

Documentation

Similar Products